Monday, October 24, 2011

News from the FDA: Onfi tablets (clobazam) for Adjunctive Treatment in Lennox-Gastaut Syndrome

From the FDA:

FDA NEWS RELEASE
For Immediate Release: Oct. 24, 2011

FDA approves Onfi to treat severe type of seizures

On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United States, it was granted orphan drug designation by the FDA.

“Lennox-Gastaut syndrome is a severe form of epilepsy that causes debilitating seizures,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is a difficult condition to treat, and it will be helpful to have an additional treatment option.”

Read the full release

Labels: , ,

0 Comments:

Post a Comment

<< Home